OR WAIT null SECS
October 22, 2021
The EC approved BMS’s Opdivo (nivolumab) as a complementary treatment to chemotherapy for adult patients with certain types of gastric or esophageal cancer.
A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.
Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.
October 21, 2021
In addition to allowing booster shots of the Moderna and J&J vaccines, FDA approved heterologous booster shots.
The silver-medal ranking is given to companies who demonstrate sustainability practices that place them in the top 20% of companies rated by EcoVadis.
The $19 million contract will expand production capacity of Aptar’s Activ-Film technology, which is used in COVID-19 testing kits.
Boehringer Ingelheim’s Cyltezo (adalimumab-adbm) is the first FDA approved interchangeable biosimilar for Humira.
October 14, 2021
This acquisition grants Bionano access to BioDiscovery’s clinical software solution for variant analysis.
The collaboration between Intellia and SparingVision will work to develop genomic medicines for ocular diseases.
Enzyvant’s Rethymic is the first FDA approved treatment for congenital athymia.